|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | EUS-guided hepaticogastrostomy combined with fine-gauge antegrade stenting: a pilot study显示文摘 | Takeshi Ogura Daisuke Masuda Akira Imoto Toshihisa Takeushi Rieko Kamiyama Malak Mohamed Eiji Umegaki Kazuhide Higuchi | 2014 | Endoscopy2014，，： | 3 |
| 2 | Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis显示文摘AIM:To determine the efficacy and safety of rapid induction therapy with oral tacrolimus without a meal in steroid-refractory ulcerative colitis(UC)patients.METHODS:This was a prospective,multicenter,observational study.Between May 2010 and August 2012,49 steroid-refractory UC patients(55 flare-ups)were consecutively enrolled.All patients were treated with oral tacrolimus without a meal at an initial dose of 0.1mg/kg per day.The dose was adjusted to maintain trough whole-blood levels of 10-15 ng/m L for the first 2 wk.Induction of remission at 2 and 4 wk after tacrolimus treatment initiation was evaluated using Lichtiger’s clinical activity index(CAI).RESULTS:The mean CAI was 12.6±3.6 at onset.Within the first 7 d,93.5%of patients maintained high trough levels(10-15 ng/m L).The CAI significantly decreased beginning 2 d after treatment initiation.At 2wk,73.1%of patients experienced clinical responses.After tacrolimus initiation,31.4%and 75.6%of patients achieved clinical remission at 2 and 4 wk,respectively.Treatment was well tolerated.CONCLUSION:Rapid induction therapy with oral tacrolimus shortened the time to achievement of appropriate trough levels and demonstrated a high remission rate 28 d after treatment initiation.Rapid induction therapy with oral tacrolimus appears to be a useful therapy for the treatment of refractory UC. | Ken Kawakami Takuya Inoue Mitsuyuki Murano Ken Narabayashi Sadaharu Nouda Kumi Ishida Yosuke Abe Koji Nogami Nobuyuki Hida Hirokazu Yamagami Kenji Watanabe Eiji Umegaki Shiro Nakamura Tetsuo Arakawa Kazuhide Higuchi | 2015 | World Journal of Gastroenterology2015，21，6： | 3 |
| 3 | SJWD14101600000484显示文摘 | Takeshi Ogura Yoshitaka Kurisu Daisuke Masuda Akira Imoto Michihiro Hayashi Mohamed Malak Eiji Umegaki Kazuhisa Uchiyama Kazuhide Higuchi | 2014 | J Gastroenterol Hepatol2014，，10： | 3 |
| 4 | EUS-guided gallbladder drainage and hepaticogastrostomy for acute cholecystitis and obstructive jaundice (with video)显示文摘 | Takeshi Ogura Daisuke Masuda Akira Imoto Eiji Umegaki Kazuhide Higuchi | 2014 | Endoscopy2014，，： | 1 |
| 5 | Present status and strategy of NSAIDs-induced small bowel injury显示文摘 | Kazuhide Higuchi Eiji Umegaki Toshio Watanabe Yukiko Yoda Eijiro Morita Mitsuyuki Murano Satoshi Tokioka Tetsuo Arakawa | 2009 | Journal of Gastroenterology2009，，9： | 1 |
| 6 | Interleukin-8 Stimulates Leukocyte Migration Across a Monolayer of Cultured Rabbit Gastric Epithelial Cells (Effect Associated with the Impairment of Gastric Epithelial Barrier Function)显示文摘 | Yasuhiro Fujiwara Tetsuo Arakawa Takashi Fukuda Eiji Sasaki Koichiro Nakagawa Kei Fujiwara Kazuhide Higuchi Kenzo Kobayashi Andrzej Tarnawski | 1997 | Digestive Diseases and Sciences1997，，6： | 1 |
| 7 | Present status and strategy of NSAIDs-induced small bowel injury显示文摘 | Kazuhide Higuchi Eiji Umegaki Toshio Watanabe Yukiko Yoda Eijiro Morita Mitsuyuki Murano Satoshi Tokioka Tetsuo Arakawa | 2009 | Journal of Gastroenterology2009，，9： | 1 |
| 8 | EUS-guided hepaticogastrostomy for hepatic hilar obstruction显示文摘 | Takeshi Ogura Daisuke Masuda Akira Imoto Eiji Umegaki Kazuhide Higuchi | 2014 | Endoscopy2014，，： | 1 |
| 9 | Effects of fluorination of AB2-type alloys and of mixing with AB5-type alloys on the chargedischarge characteristics 显示文摘 | Higuchi Eiji Toyoda Eiji Li Zhoupeng | 2001 | Electrochemica Acta2001，46，8： | 1 |
| 10 | Comparative study of conventional colonoscopy and pan-colonic narrow-band imaging system in the detection of neoplastic colonic polyps: a randomized, controlled trial显示文摘 | Takuya Inoue Mitsuyuki Murano Naoko Murano Takanori Kuramoto Ken Kawakami Yosuke Abe Eijiro Morita Ken Toshina Hideo Hoshiro Yutaro Egashira Eiji Umegaki Kazuhide Higuchi | 2008 | Journal of Gastroenterology2008，，1： | 1 |
| 11 | Present status and strategy of NSAIDs-induced small bowel injury 显示文摘 | Kazuhide Higuchi Eiji Umegaki | 2009 | Gastroenterol2009，44，： | 1 |
| 12 | 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications显示文摘 | Tetsuo Arakawa MD PhD Kazuhide Higuchi MD PhD Yasuhiro Fujiwara MD PhD Toshio Watanabe MD PhD Kazunari Tominaga MD PhD Eiji Sasaki MD PhD Nobuhide Oshitani MD PhD Toshikazu Yoshikawa MD PhD Andrzej S. Tarnawski MD PhD DSc | 2005 | Digestive Diseases and Sciences2005，，1： | 1 |
| 13 | Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism显示文摘 | Eiji Sasaki Kazunari Tominaga Hikaru Kuwamura Toshio Watanabe Yasuhiro Fujiwara Nobuhide Oshitani Kazuhide Higuchi Tetsuo Arakawa | 2007 | Journal of Gastroenterology2007，，10： | 1 |
| 14 | A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth显示文摘 | Tomoe Higuchi Masumi Shimizu Atsuko Owaki Megumi Takahashi Eiji Shinya Taiji Nishimura Hidemi Takahashi | 2009 | Cancer Immunology Immunotherapy2009，，8： | 1 |
| 15 | Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients显示文摘AIM:To assess adalimumab's efficacy with concomitant azathioprine (AZA) for induction and maintenance of clinical remission in Japanese Crohn's disease (CD) patients. METHODS:This retrospective, observational, singlecenter study enrolled 28 consecutive CD patients treated with adalimumab (ADA). Mean age and mean disease duration were 38.1 ± 11.8 years and 11.8 ± 10.1 years, respectively. The baseline mean Crohn's disease activity index (CDAI) and C-reactive protein were 177.8 ± 82.0 and 0.70 ± 0.83 mg/dL, respectively. Twelve of these patients also received a concomitant stable dose of AZA. ADA was subcutaneously administered:160 mg at week 0, 80 mg at week 2, followed by 40 mg every other week. Clinical response and remission rates were assessed via CDAI and C-reactive protein for 24 wk. RESULTS:The mean CDAI at weeks 2, 4, 8, and 24 was 124.4, 120.2, 123.6, and 135.1, respectively. The CDAI was significantly decreased at weeks 2 and 4 with ADA and was significantly suppressed at 24 wk with ADA/AZA. Overall clinical remission rates at weeks 4 and 24 were 66.7% and 63.2%, respectively. Although no statistically significant difference in C-reactive protein was demonstrated, ADA with AZA resulted in a greater statistically significant improvement in CDAI at 24 wk, compared to ADA alone. CONCLUSION:Scheduled ADA with concomitant AZA may be more effective for clinical remission achievement at 24 wk in Japanese Crohn's disease patients. | Kumi Ishida Takuya Inoue Kaori Fujiwara Taisuke Sakanaka Ken Narabayashi Sadaharu Nouda Toshihiko Okada Kazuki Kakimoto Takanori Kuramoto Ken Kawakami Yosuke Abe Toshihisa Takeuchi Mitsuyuki Murano Satoshi Tokioka Eiji Umegaki Kazuhide Higuchi | 2013 | World Journal of Gastroenterology2013，19，17： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员